PRISM MarketView
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

NEW YORK, N.Y., February 29, 2024 - PRISM MediaWire - PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million ...

29 February 2024

PRISM MarketView
Investors Are Having a Cow. Plant-Based Beyond Meat (BYND) Exceeds Q4 Revenue Estimates, Promises to Steeply Cut Costs.

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - PRISM Zombie Index Leader Beyond Meat, Inc. (BYND), is seeing a big gain today as its trading close to 45% higher on its recent earnings release. However, outside of exceeding the Street’s Q4 revenu...

28 February 2024

PRISM MarketView
MindMed Closes Out 2023 with Positive Phase 2b Results for Generalized Anxiety Treatment

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) has announced its financial results for the year ended December 31, 2023, closing out a “highly productive” year with positive Phase 2b results for MM120 ...

28 February 2024

PRISM MarketView
PRISM Rare Disease Spotlight: Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Rare disease company, Capricor Therapeutics (Nasdaq: CAPR), has been granted an in-person Type-B meeting with the FDA to discuss chemistry, manufacturing and controls (CMC) plans for commercial laun...

28 February 2024

PRISM MarketView
PRISM Rare Disease Spotlight: Voyager Therapeutics Selects Development Candidate for Friedreich’s Ataxia, Triggers $5M Milestone Payment

New York, N.Y., February 27, 2024 - PRISM MediaWire - PRISM MarketView - Voyager Therapeutics (Nasdaq: VYGR) has selected a lead development candidate in its Friedreich’s Ataxia (FA) program. The company expects the program to advance into first-in-human clinical trials ...

27 February 2024

PRISM MarketView
AdTech and Media PRISM Index Leader PubMatic, Inc. Rises 27% On Earnings Beat

New York, N.Y., February 27, 2024 - PRISM MediaWire - PRISM MarketView - Digital advertising tech company PubMatic, Inc. (PUBM) has rose ~27% after announcing record earnings after the market closed on Monday. The stock is currently trading around $21/share with 1.7M sha...

27 February 2024

PRISM MarketView
Charter Communications Eyes Altice in Potential Takeover Bid

New York, N.Y., February 27, 2024 - PRISM MediaWire -PRISM MarketView - Shares in broadband communications provider, Altice USA (NYSE: ATUS) soared on Monday following reports of a potential acquisition by Charter Communications (Nasdaq: CHTR). The news of Charter’s inte...

27 February 2024

PRISM MarketView
SunPower Secures Over $300M in Financing to Fuel Expansion of Residential Solar and Storage Solutions

New York, February 23, 2024 - PRISM MarketView - PRISM MediaWire - SunPower Corp. (Nasdaq: SPWR), an emerging player in the residential solar technology and energy services sector, has successfully secured over $300 million in project financing commitments. This funding,...

23 February 2024

PRISM MarketView
PRISM Med Device Index Tech Company Vapotherm, Inc. (VAPO) Announces Fourth Quarter Earnings

New York, February 23, 2024 - PRISM MarketView - PRISM MediaWire - PRISM Emerging Med Device Index tech company Vapotherm (VAPO) specializes in the development and commercialization of innovative respiratory support devices. The company is known for its high-flow therapy...

23 February 2024

PRISM MarketView
Incannex’s Psilocybin Targets Anxiety with Positive Topline Results

New York, N.Y., February 29, 2024 - PRISM MediaWire - PRISM MarketView - Leading cannabinoid and psychedelic medicine biotechnology company, Incannex Healthcare (Nasdaq: IXHL), has achieved  positive topline results in its Phase 2 clinical trial of psilocybin in generali...

29 February 2024

PRISM MarketView
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

NEW YORK, N.Y., February 29, 2024 - PRISM MediaWire - PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million ...

29 February 2024

PRISM MarketView
Investors Are Having a Cow. Plant-Based Beyond Meat (BYND) Exceeds Q4 Revenue Estimates, Promises to Steeply Cut Costs.

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - PRISM Zombie Index Leader Beyond Meat, Inc. (BYND), is seeing a big gain today as its trading close to 45% higher on its recent earnings release. However, outside of exceeding the Street’s Q4 revenu...

28 February 2024

PRISM MarketView
MindMed Closes Out 2023 with Positive Phase 2b Results for Generalized Anxiety Treatment

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) has announced its financial results for the year ended December 31, 2023, closing out a “highly productive” year with positive Phase 2b results for MM120 ...

28 February 2024

PRISM MarketView
PRISM Rare Disease Spotlight: Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Rare disease company, Capricor Therapeutics (Nasdaq: CAPR), has been granted an in-person Type-B meeting with the FDA to discuss chemistry, manufacturing and controls (CMC) plans for commercial laun...

28 February 2024

PRISM MarketView
PRISM Rare Disease Spotlight: Voyager Therapeutics Selects Development Candidate for Friedreich’s Ataxia, Triggers $5M Milestone Payment

New York, N.Y., February 27, 2024 - PRISM MediaWire - PRISM MarketView - Voyager Therapeutics (Nasdaq: VYGR) has selected a lead development candidate in its Friedreich’s Ataxia (FA) program. The company expects the program to advance into first-in-human clinical trials ...

27 February 2024

PRISM MarketView
AdTech and Media PRISM Index Leader PubMatic, Inc. Rises 27% On Earnings Beat

New York, N.Y., February 27, 2024 - PRISM MediaWire - PRISM MarketView - Digital advertising tech company PubMatic, Inc. (PUBM) has rose ~27% after announcing record earnings after the market closed on Monday. The stock is currently trading around $21/share with 1.7M sha...

27 February 2024

PRISM MarketView
Charter Communications Eyes Altice in Potential Takeover Bid

New York, N.Y., February 27, 2024 - PRISM MediaWire -PRISM MarketView - Shares in broadband communications provider, Altice USA (NYSE: ATUS) soared on Monday following reports of a potential acquisition by Charter Communications (Nasdaq: CHTR). The news of Charter’s inte...

27 February 2024

PRISM MarketView
SunPower Secures Over $300M in Financing to Fuel Expansion of Residential Solar and Storage Solutions

New York, February 23, 2024 - PRISM MarketView - PRISM MediaWire - SunPower Corp. (Nasdaq: SPWR), an emerging player in the residential solar technology and energy services sector, has successfully secured over $300 million in project financing commitments. This funding,...

23 February 2024

PRISM MarketView
PRISM Med Device Index Tech Company Vapotherm, Inc. (VAPO) Announces Fourth Quarter Earnings

New York, February 23, 2024 - PRISM MarketView - PRISM MediaWire - PRISM Emerging Med Device Index tech company Vapotherm (VAPO) specializes in the development and commercialization of innovative respiratory support devices. The company is known for its high-flow therapy...

23 February 2024

Subscribe

Let's stay in touch!
1
2
3
4
5
We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
Cookie settings
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
Preferences
Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
Marketing cookies
Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.